Axsome Therapeutics, Inc. (AXSM) est une société cotée en bourse dans le Santé secteur, opérant dans le Biotechnologie secteur d'activité. Le siège social de l'entreprise est situé à New York City, NY, United States. Le PDG actuel est Herriot Tabuteau.
AXSM a date d'introduction en bourse 2015-11-19, 712 employés à temps plein, cotée sur le NASDAQ Global Market, une capitalisation boursière de $9.42B.
Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing novel therapies for central nervous system disorders. The company's lead candidate, AXS-05, is being evaluated for major depressive disorder, treatment-resistant depression, Alzheimer's disease agitation, and smoking cessation across Phase II and Phase III clinical trials. Its pipeline also includes AXS-07 for acute migraine treatment, AXS-12 for narcolepsy, and AXS-14 for fibromyalgia, all in late-stage development. Founded in 2012 and headquartered in New York, Axsome collaborates with leading institutions including Duke University to advance its clinical programs.
